Although no MM trial has been announced, recent preclinical studies in lenalidomide-resistant MM models with MALAT1-targeted ASOs show strong disease-relevant activity via CD38 upregulation and reduction of oxidative stress [165]. Here, MALAT1 is linked to Miyoshi myopathy.